ABSTRACT
We report here the first pharmacokinetic-pharmacodynamic relationship for ceftaroline in a preterm infant born at <28 weeks' gestational age who was given ceftaroline (8.5 mg/kg every 8 hours) for pneumonia attributable to methicillin-resistant Staphyloccocus aureus. This dose of ceftaroline was adequate to achieve the pharmacodynamic endpoint associated with efficacy for methicillin-resistant Staphyloccocus aureus.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Cephalosporins/pharmacokinetics , Infant, Premature, Diseases/drug therapy , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal/drug therapy , Anti-Bacterial Agents/administration & dosage , Cephalosporins/administration & dosage , Drug Therapy, Combination , Fatal Outcome , Female , Humans , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/blood , Infant, Premature, Diseases/microbiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Pneumonia, Staphylococcal/blood , Pneumonia, Staphylococcal/microbiology , Rifampin/therapeutic use , CeftarolineABSTRACT
Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant suffering from M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.
